News and Trends 3 Oct 2022
Oncopeptides starts European commercialization of myeloma drug in Germany
Swedish biotech company Oncopeptides AB has initiated the commercial launch of Pepaxti (melphalan flufenamide) in Germany. It marks the first…
Oncopeptides AB
- Latest Posts
News and Trends 23 Sep 2022
Knockback for drug to treat patients with relapsed or refractory multiple myeloma
A Swedish biotech company says it believes its treatment could be the ‘canary in the coalmine’ despite a knockback. The…
